Patenting Diagnostic Methods Luncheon

Description

Following the U.S. Supreme Court?s rulings in Alice Corp v. CLS Bank and Mayo Collaborative Services v. Prometheus Labs, patent laws and regulations have been in a constant state of flux in an effort to clarify the scope of patent protection available for diagnostic methods. This seminar will discuss the relevant court decisions and U.S. Patent Office policies and practices relating to patent eligibility of diagnostic methods, and provide practical guidance on how to successfully obtain patent protection for diagnostic methods.

Christopher Wight?s law practice focuses primarily on patent prosecution and strategic counseling in the life sciences and chemical sciences, specifically in the pharmaceutical, biotechnology, diagnostic/personalized medicine and medical device fields. He has practiced law for over 30 years with prominent law firms and highly successful biotechnology companies. As former Director of Intellectual Property of Immunex Corporation (acquired by Amen in 2002), Chris was responsible for Immunex?s patent portfolios covering LEUKINE and ENBREL, which is now one of the world?s highest grossing biologic drugs, with current world-wide annual revenues of approximately $8 billion. Chris also formerly served as Vice President, General Counsel, of Myriad Genetics. He currently practices with the law firm of Snow, Christensen & Martineau, representing local and national clients on a wide range of patent issues in the life sciences and chemical sciences